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Abstract
Background: Aberrations in DNA methylation patterns promote changes in gene expression
patterns and are invariably associated with neoplasia. DNA methylation is carried out and
maintained by several DNA methyltransferases (DNMTs) among which DNMT1 functions as a
maintenance methylase while DNMT3a and 3b serve as de novo enzymes. Although DNMT3b has
been shown to preferentially target the methylation of DNA sequences residing in pericentric
heterochromatin whether it is involved in gene specific methylation remains an open question. To
address this issue, we have silenced the expression of DNMT3b in the prostate-derived PC3 cells
through RNA interference and subsequently studied the accompanied cellular changes as well as
the expression profiles of selected genes.
Results: Our results demonstrate that DNMT3b depletion results in increased apoptosis and
reduced migration of PC3 cells compared to the untransfected control cells. Reduced DNMT3b
expression resulted in hypomethylation of retinoblastoma (Rb), retinoic-acid receptor β (RAR-β),
and adenomatous polyposis coli (APC) gene promoters, and also culminated in increased
expression of CDKN3 and cytochrome b5. Although DNMT3b silenced cells were found to have
reduced growth and migratory potential, there was no apparent changes in their invasive ability
compared to the parental PC3 cell line.
Conclusion: Our findings reveal that DNMT3b preferentially targets certain gene promoters in
PC3 cells and that its depletion significantly reduces growth and migration of PC3 cells.
Background
Mutations, chromosomal translocations and dysfunc-
tional epigenetic mechanisms alter gene expression pat-
terns which invariably culminate in neoplasia [1]. DNA
methylation represents one type of epigenetic modifica-
tion which influences gene expression. Given that
hypomethylation upregulates gene expression whereas
hypermethylation has the opposite effect, unprogrammed
DNA modifications that either repress tumor suppressor
gene expression or activate oncogene expression are likely
to promote uncontrolled cellular proliferation [2].
DNMT1, DNMT3a and DNMT3b are the three main DNA
methyltransferases responsible for establishing DNA
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methylation patterns during development as well as
maintaining them in differentiated cells [3]; DNMT2 rep-
resents a fourth member of the family, but its involvement
in promoting DNA methylation remains unclear [4].
DNMT1 fully methylates hemimethylated CpG residues
in DNA. As a maintenance methylase DNMT1 associates
with proliferating cell nuclear antigen (PCNA) and is
found at the DNA replication forks during S-phase.
Recently, a novel protein UHRF1 was identified which
binds to hemimethylated DNA and recruits DNMT1; this
protein co-localizes with DNMT1 at replication foci dur-
ing the S-phase of cell cycle [5].
DNMT3a and DNMT3b consist of 908 and 859 amino
acids, respectively, and function as de novo DNA methyl-
ases [6]. Both enzymes are abundant in embryos, but their
expression in differentiated somatic cells which do not
require new methylation is very low [7-10]. Accumulation
of 5-methylcytosine epimutations by aberrant DNMT1,
DNMT3a and 3b expression has been found to silence
tumor suppressor genes including APAF, p16 and
RASSF1A [11-13]. Many primary tumors have been found
to contain high levels of these enzymes [14,15].
The essential role of DNMT1, DNMT3a and DNMT3b on
embryonic development is well known but how depend-
ent these proteins are on each other for function in differ-
ent types of normal as well as cancerous cells remains
elusive. Cell-based, biochemical genetic studies have
revealed that a complex interplay exists between these
enzymes. The picture that has emerged for DNMT3b in
particular is especially conflicting because its depletion
from different human cells has been found to produce
extremely variable effects [16-18]. In this study we have
silenced the expression of DNMT3b in prostate cancer
derived PC3 cells, which have not been studied previ-
ously, and determined its consequences on gene specific
methylation and expression as well as on cellular proc-
esses such as apoptosis and cell migration.
Methods
Cell Culture
PC3 cell line was obtained from American Type Culture
Collection (ATCC, Manassas, VA) and maintained in
RPMI with 10% fetal bovine serum, 2 mM L-glutamine,
and 100 U/ml penicillin + streptomycin sulfate (Invitro-
gen).
Transfections
Plasmids psiRNA™ is a family of expression vectors
designed to generate shRNAs from RNA III promoter
(Invivogen Inc.). PC3 cells were transfected with a mock
plasmid as well as a validated plasmid expressing shRNA
that specifically targets DNMT3b mRNAs to produce con-
trol and psiDNMT3b cell lines, respectively. psiDNMT3b
harbors a GFP:zeocin fusion cassette for selection and
assessing transfection efficiency. Transfections were car-
ried out using 3 μl of Fugene-6 (Roche Inc) and 1 μg of
plasmid DNA. After 48 hours of transfection, cells were
trypsinized, diluted 1:15 and placed in a 50 μg/ml zeocin
containing medium, which was replaced with fresh
medium every 3 days. After 3 weeks, resistant colonies
(~200–300 clones) were trypsinized, combined in pools,
cultured in selection medium, and expanded into cell
lines.
PCR
RT-PCR was performed to validate silencing of the target
gene in PC3 cells. Total RNA was extracted from control as
well as silenced PC3 cell line using Trizol (Invitogen).
Reverse transcription was carried out using First-Strand
Reverse Transcription kit (Invitogen) and 1 μg of total
RNA. Subsequently, 2 μl of RT reaction was used in PCR.
Primer sets corresponding to DNMT3b gene were used
with sequences as previously described [19]. Semi-quanti-
tative RT-PCR for DNMT3b was carried out using the fol-
lowing thermocycling conditions: 94°C for 2 minutes (1
cycle); 94°C for 30 seconds, 60°C for 1 minutes, 72°C for
1 minute (25 cycles); and 72°C for 7 minutes. Primer sets
for CDKN3 and cytochrome b5 were purchased from
Superarray Biosciences. Thermocycling conditions for
amplification of CDKN3 and cytochrome b5 were: 94°C
for 2 minutes (1 cycle); 94°C for 30 seconds, 55°C for 40
seconds, 72°C for 1 minute (25 cycles); and 72°C for 7
minutes.
Western Blotting
Extracts from control and DNMT3b silenced cell lines
were prepared by resuspending cell pellets (~2 × 105 cells)
in sample loading buffer [0.125 M Tris-HCl (pH 6.8), 4%
SDS, 20% glycerol and 10% 2-mercaptoethanol]. Approx-
imately 50 μg of the protein was separated by electro-
phoresis on a 10% SDS-PAGE and the gel contents
transferred to nitrocellulose membrane (Amersham).
After blocking overnight at 4°C in 5% nonfat dry milk
prepared in TBST, the membrane was probed with a
1:1000 dilution of DNMT3b, caspase 3 and MCM2 anti-
bodies (Santa Cruz Biotech) for 1–2 hours at room tem-
perature. Membranes were washed with TBST, incubated
with the appropriate HRP-conjugated secondary antibody
and subsequently developed with the enhanced chemilu-
minescence (ECL) western blotting system (Amersham).
β-actin was included as the internal loading control and
was detected using a specific antibody (Santa Cruz Bio-
technology).
MTT Assay
Cellular proliferation was measured by the 3-(4,5-dime-
thyl thiazol-2-yl)-2,5-diphenyl tetrazolium bromide
(MTT) proliferation assay kit (ATCC) according to theCancer Cell International 2008, 8:13 http://www.cancerci.com/content/8/1/13
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manufacturer's instructions. Briefly, 104 cells were seeded
in 96-well plates and cultured in 5% FCS for 24 hours.
Before testing, 10 μl of MTT labeling reagent (5 mg/mL
MTT) was added to cells and the mixture incubated for a
further 4 hours at 37°C. 100 μl of solubilizing reagent was
then added and the plate incubated overnight at 37°C to
dissolve formazan crystals. Absorbance was measured at
OD595  in a Chameleon multilabel detection platform
(Hidex Inc.). Each assay was carried out in triplicate and
each experiment was repeated at least twice.
Acridine Orange and Ethidium Bromide (AO/EB) Staining
Apoptosis was measured by AO/EB staining as described
previously with some modifications [20]. Briefly 25 μl of
cell suspension (1–2 × 105 cells) was added to 25 μl of 1:1
AO/EB solution (both AO and EB prepared at 100 μg/ml
in PBS) and loaded on a hemocytometer under a cover
slip. Cells were counted on a grid using visible light and
then dead cells (stained orange with ethidium bromide)
were counted under fluorescence. Student T-test was per-
formed to assess the statistical significance of obtained
data.
Boyden Chamber Invasion Assay
Boyden chamber invasion assay was performed as
described [21] with some modifications. A fixed number
of cells (5 × 104 cells/ml) in serum-free medium were
placed in the upper chamber of the Boyden chamber pre-
coated with Matrigel (polyvinyl pyrrolidone-free polycar-
bonate filter with 8-μm pore size) inserts (BD Pharmin-
gen, San Diego, CA). The lower chamber contained
serum-free media with epidermal growth factor (50 ng/
ml). Cells were incubated for 24 hours, after which
medium was removed and the upper surface of the inva-
sion chamber insert was scrubbed with a cotton swab
thrice in each direction. The membrane was removed
from the invasion chamber insert with a scalpel, was fixed
with 100% methanol and stained with Giemsa Wright
stain. Cells were counted at 200× magnification in five dif-
ferent random fields by two independent observers. Stu-
dent's T-test was performed to assess statistical
significance of obtained invasion data.
Cell Migration Assay
Stably transfected cells were sub-cultured in 6-well plates
and incubated in RPMI with 10% FBS. Confluent monol-
ayer cells were starved for serum and growth factors in
RPMI for 24 h and beeline or river (1 mm thick) was cre-
ated using a 10 μl micropipette tip.
Cells were washed and incubated in serum free medium.
Cell migration was monitored at 12-hr interval and pho-
tographed.
Methylation-Specific PCR (MSP)
Genomic DNA was extracted from control and
psiDNMT3B transfected cells by using DNA extraction kit
(Qiagen, Hilden). 2 μg of DNA was subjected to bisul-
phite modification using Methyl-Easy bisulphite modifi-
cation kit (Human Genetic Signatures, Sydney, Australia).
Bisulphite converted DNA was then amplified with two
sets of primers (methylated and unmethylated) for the
following genes RASSF1a, APC, RAR-beta, RB1, hMLH1,
Survivin, DAPK, BRCA, TIMP3, VHL, p16, PTEN, CDH1,
CASP8, hTERTc, and RASSF1c; DNA sequences of primers
employed for PCR are listed in Table-1. PCRs were carried
out on Master Cycler (Eppendorf) using the following
conditions: 95°C for 10 minutes, followed by 40 cycles of
95°C for 30 seconds, 55°C for 30 seconds, and 72°C for
1 minute followed by a final extension at 72°C for 7 min-
utes. Each PCR was carried out in 25 μl reaction volume
containing 1× AmpliTaq Gold PCR buffer II (Applied Bio-
systems), 1 unit AmpliTaq Gold polymerase (Applied bio-
systems), 1 μM forward primer, 1 μM reverse primer, 0.25
mM dNTPs each,1.5 mM MgCl2 and 2 μl of DNA. Bisul-
phite converted Sss I methylase-treated WBC DNA served
as positive control.
Genechip Expression Arrays
Prostate cancer specific oligo-GEarray (SuperArray Bio-
sciences) was used for gene expression profiling. Briefly,
total RNA was extracted from psiDNMT3b and mock
transfected cells by Arraygrade™ Total RNA isolation kit
(SuperArray Biosciences). Integrity of RNA was assessed
by running 1 μg of RNA on denaturing agarose gel. Truela-
beling AMP-2.0 kit (SuperArray Biosciences) was used for
synthesizing biotin labeled cRNA. Labeled probe was
hybridized to prostate cancer specific oligoGEarray. Arrays
were developed using chemiluminescent detection kit and
X-ray film was used to capture images. For analysis, the X-
ray film pattern was scanned and loaded on the GEarray
expression Analysis Suite – a web based software from
Superarray. The relative expression of 288 genes was
assessed using this software and the respective signals nor-
malized against the spot intensities of β-actin, GAPDH
and ribosomal proteins on the membrane.
Results
DNMT3b deficiency in colon cancer cells results in a very
nominal 3% reduction in DNA methylation levels and
does not appear to alter the methylation status of any
genes [17]. To determine whether depletion of DNMT3b
in PC3 cells has the same effect, RNA interference was
employed to reduce its expression. This was carried out by
stably transfecting a plasmid from which a shRNA is syn-
thesized, processed and supposedly incorporated into an
RNA-induced silencing complex (RISC) that specifically
targets DNMT3b mRNA; this plasmid also expresses GFP
which permitted facile visual inspection of cells throughCancer Cell International 2008, 8:13 http://www.cancerci.com/content/8/1/13
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epifluorescence microscopy. After maintaining trans-
fected cells in zeocin-containing medium for two weeks,
DNMT3b mRNA and protein levels were determined
using RT-PCR and Western blotting. Such analysis
revealed that even though 100% of the cells were GFP-
positive, expression of DNMT3b was reduced by approxi-
mately 75% at the protein level relative to the mock-trans-
fected parental cells (Figure-1A). Additional attempts at
further reducing the DNMT3b expression did not prove
successful. Importantly, DNMT3b down-regulation did
not impact DNMT1 expression in the engineered PC3
cells as gauged by RT-PCR and Western blot analyses (data
not shown).
Phenotypic changes in PC3 cells should not be observed
if other DNMTs are able to compensate for DNMT3b loss.
To assess whether any phenotypic changes were brought
about by depletion of DNMT3b, we compared cellular
processes such as proliferation, apoptosis, invasion and
migration in the engineered cells with the control mock-
transfected PC3 cells. Proliferation analyses, as carried out
by the MTT assay, revealed that cells with reduced levels of
DNMT3b grew significantly more poorly than the control
cells after 24 and 48 hours (p-value, < 0.0002, and <
0.0001 respectively; Figure-1B). The expression of MCM2,
a proliferation marker, was determined in both cell lines
and showed more than 50% reduction in DNMT3b
depleted cells as compared to control cells (Figure-1D).
This growth defect was attributed to increased apoptosis
which in DNMT3b deficient cells was found to be approx-
imately 35% more than the control cells (p-value <
0.0011; Figure-1C). Interestingly, caspase-3 expression
was found to be increased two-fold in DNMT3b silenced
cells which exhibited enhanced apoptosis and poor
growth (Figure-1E).
Boyden-chamber assays revealed that the invasive poten-
tial of control and DNMT3b silenced PC3 cells was equiv-
alent (Figure-2A). Invasion is a two-step process
comprised of migration and membrane (matrigel in
Boyden chamber assays) breakdown; to be invasive cells
must be able to execute both steps competently. Given
Table 1: DNA sequences of all primers used in methylation sensitive PCR
GENE METHYLATED PRIMER SEQUENCE UNMETHYLATED PRIMER SEQUENCE
RASSF1A F 5' GTGTTAACGCGTTGCGTATC 3' F 5'TTTGGTTGGAGTGTGTTAATGTG 3'
R 5' AACCCCGCGAACTAAAAACGA 3' R CAAACCCCACAAACTAAAAACAA 3'
Survivin F 5' GGCGGGAGGATTATAATTTTCG 3' F 5' GGTGGGAGGATTATAATTTTTG 3'
R 5' CCGCCACCTCTACCAACG 3' R 5' CCACCACCACCACCTCTAC 3'
DAPK1 F 5'GGATAGTCGGATCGAGTTAACGTC 3' F 5'GGATAGTTGGATTGAGTTAAYGTC 3'
R 5' CCCTCCCAAACGCCGA 3' R 5' CAAATCCCTCCCAAACACCAA 3'
APC F 5' TATTGCGGAGTGCGGGTC 3' F 5' GTGTTTTATTGTGGAGTGTGGGTT 3'
R 5' TCGACGAACTCCCGACGA 3' R 5' CCAATCAACAAACTCCCAACAA 3'
RAR-β F 5' TCGAGAACGCGAGCGATTCG 3' F 5' TTGAGAATGTGAGTGATTTGA 3'
R 5' GACCAATCCAACCGAAACGA 3' R 5' AACCAATCCAACAAAACAA 3'
hLMH1 F 5'ACGTAGACGTTTATTAGGGTCGC 3' F 'TTTTGATGTAGATGTTTTATTAGGGTTGT 3'
R 5'CCTCATCGTAACTACCGCG 3' R 5'ACCACCTCATCATAACTACCCACA 3'
RB1 F 5'GGGAGTTTCGCGGACGTGAC 3' F 5'GGGAGTTTTGTGGATGTGAT 3'
R 5'ACGTCGAAACACGCCCCG 3' R 5'ACATCAAAACAACCCCA 3'
BRCA F 5'GGTTAATTTAGAGTTTCGAGAGACG 3' F 5' GGTTAATTTAGAGTTTTGAGAGATG 3'
R 5' TCAACGAACTCACGCCGCGCAATCG 3' 5' TCAACAAACTCACACCACACAATCA 3'
TIMP3 F 5' CGTTTCGTTATTTTTTGTTTTCGGTTTC 3' F 5' TTTTGTTTTGTTATTTTTTGTTTTTGGTTTT 3'
R 5' CCGAAAACCCCGCCTCG 3' R 5' CCCCCAAAAACCCCACCTCA 3'
VHL F 5' TGGAGGATTTTTTTGCGTACGC 3' F 5' GTTGGAGGATTTTTTTGTGTATGT3'
R 5' GAACCGAACGCCGCGAA 3' R 5' CCCAAACCAAACACCACAAA 3'
p16 F 5' TTATTAGAGGGTGGGGCGGATCGC 3' F 5' TTATTAGAGGGTGGGGTGGATTGT 3'
R 5' ACCCCGAACCGCGACCGTAA 3' F 5' CAACCCCAAACCACAACCATAA 3'
PTEN F 5' GGTTTTTCGAGGCGTTCG 3' F 5' TGGTTTTTTGAGGTGTTTG 3'
R 5' CGCCTCACAACGACTCAACT 3' R 5' TTCCATCATAACTACAACTTCCA 3'
CDH1 F 5' GTGGGCGGGTCGTTAGTTTC 3' F 5' GGTGGGTGGGTTGTTAGTTTTGT 3'
R 5' CTCACAAATACTTTACAATTCCGACG 3' R 5' AACTCACAAATCTTTACAATTCCAAC 3'
CASP8 F 5' TAGGGGATTCGGACATTGCGA 3' F 5' TAGGGGATTTGGAGATTGTGTA 3'
R 5' CGTATATCTACATTCGAAACG 3' R 5' CCATATATATCTACATTCAAAACAA 3'
hTERTc F 5' GACGTAAAGTTTTTTTCGGACG 3' F 5' GTAAAGATGTAAAGTTTTTTTTGGATG 3'
R 5' ACCCGATACGCTACCGAACG 3' R 5' CCACAACCCAATACACTACCA 3'
RASSF1c F 5' AGTTTGGATTGTCGGTTTCG 3' F 5' GGAGTTTGGATTGTTGGTTTTG 3'
R 5' TCACAAACCCCACCTACCAC 3' R 5' CACCCCCAAAAATAACCTCAT 3'
DNA sequences of methylated and unmethylated set of primers of 16 tumor suppressor genes studied by methylation-specific PCR.Cancer Cell International 2008, 8:13 http://www.cancerci.com/content/8/1/13
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Silencing of DNMT3b expression in PC3 cells and validation of cell lines Figure 1
Silencing of DNMT3b expression in PC3 cells and validation of cell lines. A. Total RNA as well as protein was 
extracted from mock (control), and psiDNMT3b transfected PC3 cells and subjected to semi-quantitative RT-PCR analysis and 
Western blotting. β-actin was used as loading control. B. Affect of DNMT3b silencing on cell proliferation. Cells were grown 
and their respective rate of proliferation was measured by MTT assay after 24 and 48 hours. Absorbance was measured at 595 
nm. C. Apoptosis was studied quantitatively by ethidium bromide and acridine orange staining of control and DNMT3b 
silenced cells. D. Expression analysis of MCM2. Total protein from mock (control), and psiDNMT3b transfected PC3 cells was 
subjected to Western blotting to determine expression of MCM2. β-actin was used as loading control. E. Expression analysis of 
caspase 3. Total protein from mock (control), and psiDNMT3b transfected PC3 cells was subjected to Western blotting to 
determine expression of caspase 3. β-actin was used as loading control.Cancer Cell International 2008, 8:13 http://www.cancerci.com/content/8/1/13
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that DNMT3b deficient cells were no different from con-
trol cells in terms of their invasive potential we reasoned
that they might be compromised with their ability to
migrate. Towards that end, migratory potential of both
cell lines was compared using the wound healing assay.
This experiment demonstrated that down-regulation of
DNMT3b in PC3 cells significantly reduced their ability to
trespass through a trough even after 48 hours (Figure-2B).
Previous reports have shown that silencing of DNMT3b
does not appear to affect DNA methylation of any of the
genes in cells derived from colon cancer. To determine
whether the same affect of DNMT3b down-regulation is
observed in prostate derived PC3 cells, we evaluated the
methylation status of 16 tumor suppressor gene promot-
ers using methylation-specific PCR (MSP). For this,
genomic DNA from control as well as DNMT3b silenced
cells was isolated, 5-methylcytosine residues chemically
converted to uracil by bisulfite treatment, and subse-
quently employed this DNA as template in PCR reactions
with methylation-senstitive as well as insensitive primer
pairs. To ascertain that the employed primer sets can reli-
ably distinguish methylated annealing sites from those
which are unmethylated, genomic DNA was isolated from
white-blood cells and one-half of it methylated to satura-
tion with Sss1 methylase while the other half was used
without any processing. Data from this experiment dem-
onstrated clearly that in the diploid PC3 genome both
promoters of the RASSF1A and p16 genes are hypermeth-
ylated and remain that way even after DNMT3b expres-
sion diminished (Figure-3). In contrast, both copies of
genes encoding survivin, DAPK1, hLHM1, BRCA1, VHL,
PTEN, CDH1, CASP8, hTERTc and RASSF1c in genome of
control PC3 cells were found to be hypomethylated, and
as expected, remained that way even after DNMT3b
expression was curtailed (Figure-3). Also notable is the
fact that gene promoters for adenomatous polyposis coli
(APC), retinoic acid receptor-beta (RAR-β), retinoblastoma-1
(Rb1) and tissue inhibitor of metalloprotein-3 (TIMP-3) are
differentially methylated on the two alleles. Strikingly,
this experiment unequivocally demonstrated that from
the 16 tumor suppressor genes that were scrutinized
DNMT3b down-regulation caused specific loss of methyl-
ation at the promoters of APC, RAR-β, and Rb1 genes (Fig-
ure-3).
To gain further insight into the consequences of DNMT3b
silencing on the expression levels of various genes, a gene-
chip array spotted with oligonucleotides representing a
total of 288 (including 25 controls) genes found to be dif-
ferentially expressed in prostate cancers was screened with
biotin-labeled cRNA probes prepared from RNA that was
purified from control and DNMT3b silenced PC3 cells
(Figure-4A). The results of this experiment clearly showed
that as compared to control cells, DNMT3b deficiency
increased expression of caspase 7, cytochrome b5, CDKN3
and protein kinase-C by 2, 3, 6 and 21-fold, respectively
(Figure-4B). The data from this experiment was further
validated by performing semi-quantitative RT-PCR for
CDKN3 and cytochrome b5 genes which showed significant
up-regulation of these genes in DNMT3b silenced cell
lines compared to the control cells (Figure-4C &4D).
Cellular invasion and migration assays Figure 2
Cellular invasion and migration assays. A. Boyden chamber invasion assays were carried out on control and DNMT3b 
silenced cells and the number of cells invading matrigel was determined. B. Wound healing migration assays were carried out as 
described. Panels show wounds in control, and DNMT3b depleted cells at 0 and 48 hours.Cancer Cell International 2008, 8:13 http://www.cancerci.com/content/8/1/13
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Discussion
In this report, we have shown that down-regulation of
DNMT3b expression in PC3 cells is associated with loss of
methylation at three (i.e., APC, RAR-β and Rb1) of the 16
gene promoters that were examined. Alleles for all three
affected genes were found to be differentially methylated
in mock-transfected PC3 cells, but DNMT3b silencing left
both copies of each gene in a hypomethylated state. Addi-
tionally, from the 263 genes implicated in prostate cancer
that were screened, four (i.e., caspase-7, cdkn3, cytochrome
b5 and protein kinase-C) were found to be highly expressed
(i.e., >2-fold) in DNMT3b silenced cells as compared to
the controls; among the genes which were up-regulated,
expression of CDKN3 increased 6-fold while that of pro-
tein kinase-C was found to be 21-fold higher. Although
previous studies have shown that DNMT3b preferentially
methylates satellite DNAs, this is the first report which
demonstrates that DNMT3b also contributes to the spe-
cific silencing of various protein encoding genes.
Cell proliferation was dramatically affected by reduced
DNMT3b levels and this was attributed to enhanced
apoptosis suggesting that DNMT3b targets a set of genes
whose products inhibit apoptosis. Interestingly, DNMT3b
deficiency in PC3 cells did not affect their invasive poten-
tial but significantly compromised their ability to migrate
indicating that the expression of genes which promote cell
migration is influenced by DNMT3b mediated DNA
methylation. Given that DNMT3b silencing promotes
expression of proapoptotic genes such as caspase-7 and
cytochrome b5, and negatively acting cell cycle regulators
like Rb1 and CDKN3 explains why the host cells prolifer-
ate so poorly. This phenomenon is not restricted to PC3
cells only but has also been observed in cells obtained
from human colorectal, breast and lung cancers [16,18].
The most striking aspect of our findings is that DNMT3b
loss selectively led to the demethylation of APC, Rb1 and
RARβ gene promoters. Moreover, even though the meth-
ylation status of the caspase-7, CDKN3, cytochrome b5 and
protein kinase-C gene promoters was not determined, the
fact that their expression levels increased in response to
DNMT3b loss implies that these gene promoters are also
targeted by this methylase. It is important to note that
even though DNMT3b levels were reduced by 75%, the
remaining 25% of methylase activity was insufficient to
maintain the methylation status at several of the gene pro-
moters.
Our findings are different from those reported by Rhee et
al. who observed that DNMT3b knockout did not affect
methylation of any of the examined genes but only caused
demethylation of juxtacentromeric satellite-2 in colon
cancer cells [17]. The impact of DNMT3b loss in PC3 cells
appears to be more dramatic since the methylation and
expression of many genes was affected. It should be noted
however that PC3 cells contain moderate levels of
DNMT1 and DNMT3a which are not affected when
DNMT3b is silenced (data not shown); like PC3, colon
cancer cells also express DNMT1 and DNMT3a. Since
both DNMT1 and DNMT3a are unable to compensate for
DNMT3b loss, it is plausible that colon carcinoma cells
contain an unidentified component of the DNA methyla-
tion pathway which is absent in PC3 cells.
Only a small number of genes were included in this study
and the one reported by Rhee et al. To clearly discern the
differences that exist between DNMT3b silenced PC3 and
colon cancer cells, will require detailed gene expression as
well as whole genome analysis in order to identify the sets
of gene loci that are most impacted by DNMT3b silencing.
DNA methylation was once assumed to be a simple proc-
ess dependent entirely on DNMT1, DNMT3a and
DNMT3b. However a number of biochemical, genetic and
Methylation specific PCR analyses of RASSF1a, APC,  RAR-β, RB1, hMLH1, Survivin, DAPK, BRCA, TIMP3,  VHL, p16, PTEN, CDH1, CASP8, hTERTc, and  RASSF1c genes in mock and psiDNMT3b transfected  cells Figure 3
Methylation specific PCR analyses of RASSF1a, APC, 
RAR-β, RB1, hMLH1, Survivin, DAPK, BRCA, TIMP3, 
VHL, p16, PTEN, CDH1, CASP8, hTERTc, and 
RASSF1c genes in mock and psiDNMT3b transfected 
cells. Presence of PCR product indicates methylated (lane 
M) or unmethylated (lane U) alleles.Cancer Cell International 2008, 8:13 http://www.cancerci.com/content/8/1/13
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cell-based studies have found that the interplay between
these enzymes is complex and most likely dependent on
additional proteins. By demonstrating that silencing of
DNMT3b in prostate derived cells has a more dramatic
effect than its absence in colon carcinoma cells, this work
also supports the notion that other yet unidentified fac-
tors are likely to influence DNMT3b activity.
Conclusion
Taken together our data demonstrates that silencing
DNMT3b expression causes hypomethylation of specific
sets of gene promoters and increases expression of distinct
set of genes. Phenotypic characterization of DNMT3b
silenced PC3 cells showed that they grew poorly and had
reduced migratory potential as compared to the control
cells.
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